^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CAD-ALK fusion

    i
    Other names: NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor, CAD, Carbamoyl-Phosphate Synthetase 2 Aspartate Transcarbamylase And Dihydroorotase, CAD Protein, Multifunctional Protein CAD, CAD Trifunctional Protein, EIEE50, CDG1Z, GATD4
    Entrez ID:
    238; 790
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    10ms
    Anaplastic Lymphoma Kinase (ALK) Inhibitors Show Activity in Colorectal Cancer With ALK Rearrangements: Case Series and Literature Review. (PubMed, Oncologist)
    Both fluorouracil, leucovorin, and oxaliplatin (FOLFOX) and bevacizumab combined with 5-fluorouracil, l-leucovorin, and irinotecan (FOLFIRI) proved ineffective against the disease...The patient was initially treated with ensartinib monotherapy for 9 months, then with ensartinib combined with local radiotherapy and fruquintinib for another 4 months for isolated hilar hepatic lymph node metastasis. The patient experienced disease progression with an acquired ALK G1202R resistance mutation that responded well to lorlatinib...However, the patient responded remarkably well to alectinib. Our report emphasizes the importance of gene detection in the treatment of malignant tumors, and the significance of ALK mutations in CRC.
    Review • Journal
    |
    ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4)
    |
    ALK positive • ALK rearrangement • EML4-ALK fusion • ALK fusion • ALK G1202R • CAD-ALK fusion • EML4-ALK G1202R
    |
    Avastin (bevacizumab) • 5-fluorouracil • Alecensa (alectinib) • Lorbrena (lorlatinib) • oxaliplatin • irinotecan • Ensacove (ensartinib) • Fruzaqla (fruquintinib) • leucovorin calcium
    almost4years
    Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions. (PubMed, Clin Cancer Res)
    RTK fusions in CRC are a rare but important disease subgroup that occur in RAS and BRAF wild-type tumors. Despite enrichment in acquired MMR-D tumors, RTK fusions also occur in microsatellite-stable CRC and provide an important therapeutic target.
    Journal
    |
    BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • MLH1 (MutL homolog 1)
    |
    BRAF V600E • MSI-H/dMMR • BRAF V600 • ALK mutation • ROS1 fusion • ALK translocation • GOPC-ROS1 fusion • CAD-ALK fusion
    |
    Xalkori (crizotinib) • Rozlytrek (entrectinib) • Alecensa (alectinib)